Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations by Hubner, Richard A. et al.
Excision Repair Cross-Complementation Group 1 (ERCC1)
Status and Lung Cancer Outcomes: A Meta-Analysis of
Published Studies and Recommendations
Richard A. Hubner
1, Richard D. Riley
2, Lucinda J. Billingham
3,4, Sanjay Popat
5,6*
1Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom, 2Department of Public Health, Epidemiology and Biostatistics,
University of Birmingham, Birmingham, United Kingdom, 3Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom, 4MRC
Midland Hub for Trials Methodology Research, University of Birmingham, Birmingham, United Kingdom, 5Department of Medicine, Royal Marsden NHS Foundation Trust,
London, United Kingdom, 6Molecular Genetics Group, Imperial College, London, United Kingdom
Abstract
Purpose: Despite discrepant results on clinical utility, several trials are already prospectively randomizing non-small cell lung
cancer (NSCLC) patients by ERCC1 status. We aimed to characterize the prognostic and predictive effect of ERCC1 by
systematic review and meta-analysis.
Methods: Eligible studies assessed survival and/or chemotherapy response in NSCLC or SCLC by ERCC1 status. Effect
measures of interest were hazard ratio (HR) for survival or relative risk (RR) for chemotherapy response. Random-effects
meta-analyses were used to account for between-study heterogeneity, with unadjusted/adjusted effect estimates
considered separately.
Results: 23 eligible studies provided survival results in 2,726 patients. Substantial heterogeneity was observed in all meta-
analyses (I
2 always .30%), partly due to variability in thresholds defining ‘low’ and ‘high’ ERCC1. Meta-analysis of
unadjusted estimates showed high ERCC1 was associated with significantly worse overall survival in platinum-treated
NSCLC (average unadjusted HR=1.61, 95%CI:1.23–2.1, p=0.014), but not in NSCLC untreated with chemotherapy (average
unadjusted HR=0.82, 95%CI:0.51–1.31). Meta-analysis of adjusted estimates was limited by variable choice of adjustment
factors and potential publication bias (Egger’s p,0.0001). There was evidence that high ERCC1 was associated with reduced
response to platinum (average RR=0.80; 95%CI:0.64–0.99). SCLC data were inadequate to draw firm conclusions.
Conclusions: Current evidence suggests high ERCC1 may adversely influence survival and response in platinum-treated
NSCLC patients, but not in non-platinum treated, although definitive evidence of a predictive influence is lacking.
International consensus is urgently required to provide consistent, validated ERCC1 assessment methodology. ERCC1
assessment for treatment selection should currently be restricted to, and evaluated within, clinical trials.
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Introduction
Lung cancer is the commonest cause of cancer death globally,
accounting for around 1.3 million deaths per year [1]. Despite
advances in therapeutics, survival from both major subtypes (non-
small cell lung cancer (NSCLC) and SCLC) remain poor, with
only around 5% of all patients reaching 5 years. Standard of care
for both advanced NSCLC and SCLC is platinum-based doublet
chemotherapy, with non-platinum doublets inferior [2,3]. In
NSCLC platinum doublets are associated with response rates of
25–30% [4]. A number of tumour biomarkers have been
investigated for prognostic and predictive utility when considering
systemic therapy, and prominent amongst these is excision repair
cross-complementation group 1 (ERCC1) protein.
ERCC1 is the rate-limiting member of the nucleotide excision
repair pathway (NER), one of at least 5 overlapping biochemical
pathways by which altered DNA sequences can be restored to
base-line. Abrogation of these pathways has been both associated
with carcinogenesis [5], and targeted as a therapeutic mechanism
[6]. The NER pathway functions to remove bulky DNA lesions
[5], including tobacco-associated adducts formed by carcinogen
exposure [7]. Mechanisms of platinum cytotoxicity include
forming bulky DNA adducts leading to both inter-and intra-
strand cross-link generation, which results in apoptosis unless
repaired.
The critical role of ERCC1 in carcinogen and platinum adduct
removal by NER has led to a number of studies reporting the
relationship between ERCC1 status and survival in lung cancer
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both as a prognostic biomarker, and for a predictive influence in
determining benefit from platinum-directed therapy, with esti-
mates between studies differing considerably.
We performed a systematic review and, where possible, meta-
analysis of study outcomes to produce evidence-based results on
the prognostic and predictive utility of ERCC1 status in lung
cancer, and identify further research needs.
Methods
Systematic review and meta-analysis was performed according
to Cochrane [8], QUORUM [9], and PRISMA [10] guidelines.
Eligibility Criteria
English language published studies were eligible if they assessed
association of ERCC1 expression with survival or tumour response
in NSCLC or SCLC patients. The primary outcomes of interest
were overall survival (OS), event-free survival (EFS) and tumour
response to chemotherapy, as defined by the contributing studies.
For publications with overlapping datasets the smaller series was
excluded.
Identification of Studies
The search for studies was performed in duplicate (SP and
RAH) using the electronic database PubMed (http://www.
pubmed.com) until 10th August 2009. The search strategy used
the keywords ‘‘lung cancer,’’ ‘‘NSCLC’’, or ‘‘SCLC’’, and
‘‘ERCC1’’. Bibliographies of eligible studies, review articles and
other relevant publications were also hand-searched to identify
additional studies. Data from review articles, abstracts, and letters
were not included.
Data extraction
Study characteristics were extracted from the full published
article and summarized in a consistent manner to aid comparison.
Methodology of ERCC1 analysis was categorized, including the
threshold used to dichotomize ERCC1 as ‘‘high’’ and ‘‘low’’.
For platinum or non-platinum based chemotherapy treatment
groups within each study, the log hazard ratio (log(HR)) estimate
and its variance were extracted (log ratio of survival risk in ERCC1
high group versus ERCC1 low group). When not directly reported
the log(HR) and its variance were estimated [11,12], from other
data, such as log rank test statistics and p values, and number of
patients and events in each group, using the methods of Parmar
et al [13,14]. Where relevant effect estimates were not obtainable
using the methods above, or through direct contact with
corresponding authors, the study was excluded from the meta-
analysis. Both unadjusted and adjusted HR estimates were sought
for each study, and the choice of adjustment factors recorded.
In addition, we sought to extract the log relative risk (log(RR))
estimate and its variance indicating the log of the ratio of the risk
of tumour response (response versus non-response) to platinum-
based systemic therapy in the ERCC1 ‘‘high’’ group versus
ERCC1 ‘‘low’’ group.
Statistical Analysis
Direct evidence of ERCC1 as a predictive biomarker for
platinum-based chemotherapy, defined by the interaction between
platinum-based versus non-platinum-based chemotherapy and
ERCC1 status within randomised controlled trials, was summa-
rised where available. Indirect evidence of predictive influence was
obtained by collating evidence on the prognostic effect of ERCC1
in platinum-based treated groups and non-platinum-based treated
groups available separately from studies, and on the relationship
between ERCC1 and radiological response to platinum-based
chemotherapy.
Heterogeneity between studies was expected, hence extracted
study log(HR) or log(RR) estimates and their variances were
pooled using a random effects meta-analysis which accounts for
such heterogeneity; estimates the average (‘summary’) HR across
studies and its confidence interval (CI); and provides a prediction
interval for the true hazard ratio in an individual study setting
[15,16].
The impact of between-study heterogeneity in our meta-
analyses was assessed by the I
2 statistic [17]. I
2 describes the
proportion of total variation in meta-analysis estimates due to
between-study heterogeneity, and is measured from 0–100% with
increasing I
2 values indicating a larger impact of between-study
heterogeneity in the meta-analysis.
For meta-analyses including 10 or more studies we assessed the
possibility of small study effects (which indicates potential
publication bias) by performing Egger’s test, with a 10%
significance level due to the low power of this test [18].
All statistical computations were undertaken using STATA
version 10 (Stata Corporation, College Station, TX) and the
modules METAN [19], and METABIAS [20]
Results
Eligible Studies
We identified 25 eligible studies [21,22,23,24,25,26,27,28,29,
30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45] which provided
outcome data stratified by ERCC1 status (Figure 1). One of these
[25] was excluded since the data set overlapped with a larger
previously reported series [33], whilst in another [45] relevant
effect estimates could not be obtained, leaving 23 studies from 11
countries.
In four studies [28,32,36,38] outcome data were presented
separately for patients who underwent different therapeutic
strategies, and these groups were treated as separate datasets
(Table 1). Specifically, Rosell et al. [38] stratified patients into
groups who received three different chemotherapy regimes, one of
which overlapped with a larger cohort [39] and was thus excluded;
Olaussen et al. [36] reported separately on patients randomised to
either chemotherapy or observation following resection; Okuda
et al. [28] presented separate outcome data from non-randomised
cohorts who underwent either peri-operative chemotherapy or
surgery alone; and Fujii et al. [32] separately analysed outcomes
for patients undergoing neoadjuvant chemotherapy or chemor-
adiotherapy, but datapoints were not extractable for the
chemoradiotherapy group and this dataset was therefore excluded.
Two studies [23,27] reporting patients with SCLC presented
separate outcome data by stage (limited or extensive), and these
datasets were treated separately (Table 1).
Study Characteristics
Characteristics of the 23 eligible studies are summarised in
Table 1. All studies assessed ERCC1 expression retrospectively.
Six studies [31,32,35,36,38,39] assessed ERCC1 in tumours from
unselected patients enrolled into clinical trials, whilst in the
remainder patients were not accrued to a trial. The median
percentage of male patients was 76%, whilst the median of the
study age means was 61 years. Three studies [28,31,42] did not
report mean age.
OS was reported in all studies, event-free survival in nine studies
[21,22,24,26,30,32,33,34,38] (classified as progression-free surviv-
al [21,22,26,33], disease-free survival [24,32,34], time to tumour
ERCC1 and Lung Cancer Outcome
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12 studies [21,22,23,26,27,31,32,33,39,40,41,42]. Criteria used to
assess tumour response were either Response Evaluation Criteria
in Solid Tumours (RECIST) [22,33,40,41], World Health
Organization (WHO) [21,23,26,39,42], Eastern Cooperative
Oncology Group (ECOG) [32], or unspecified [27,31]. Sample
sizes of the datasets assessed for overall survival ranged from 15 to
389 (median 54; Table 1), with data from a total of 2,726 patients
available for pooling.
Of the 20 studies that reported on NSCLC, eleven
[22,26,31,33,35,38,39,41,42,43,44] included patients with inoper-
able/advanced/recurrent disease (stages IIB-IV), who received
either platinum-containing chemotherapy [26,31,33,35,38,39,41,
42,43], platinum-containing chemoradiotherapy [25,44], or non-
platinum-containing chemotherapy [38]. Whilst in the remaining
nine studies [21,24,28,29,30,32,34,36,37] patients were treated
radically undergoing resection alone [24,28,29,30,34,36,37], or
resection combined with either neoadjuvant or adjuvant cisplatin-
based chemotherapy [28,32,36] or chemoradiotherapy [21,32].
Chemotherapy regimens used in each study are detailed in
Table 1. Fifteen studies used platinum-containing regimens, with
eight using only cisplatin [25,32,35,36,38,39,42,44], one only
carboplatin [43], and either in six [21,26,28,31,33,41].
ERCC1 status assignation
ERCC1 evaluation was performed by immunohistochemistry
(IHC) in 15 studies [21,23,25,26,28,29,32,33,34,36,40,41,42,43,
44], and real-time quantitative polymerase chain reaction
(RTqPCR) in the remaining eight [24,27,30,31,32,37,38,39].
Samples evaluated were surgical resection specimens in eight
studies [24,28,29,30,33,34,36,37], biopsies of primary tumour,
involved lymph nodes, or metastases in 14 studies [21,23,26,
27,31,32,35,38,39,40,41,42,43,44], or both resection and biopsy
specimens [25]. ERCC1 status was assessed blinded to outcome
data in the majority (17/23) of studies [21,22,23,26,27,29,32,
33,35,36,38,39,40,41,42,43,44], whilst in the remaining six [24,28,
30,31,34,37] blinding information was not provided.
In the 15 studies evaluating ERCC1 expression by IHC, ten
[21,22,23,26,,32,40,41,42,43,44] evaluated biopsy specimens, three
studies [28,33,36] used tissue from resection specimens, and the
remaining two [29,34] used a tissue microarray. All used the same
monoclonal antibody (8F1), but marked heterogeneity was observed
between thresholds used to dichotomise ERCC1 status. Whilst the
majority (10/15) of studies assessed both staining extent and intensity,
thresholds varied; one study used image analyser software to evaluate
samples [34]; three studies derived a composite (H) score by
multiplying extent cell-staining score (0–3; 0=none, 1=1–9%,
Figure 1. PRISMA
10 flow chart of selection process to identify studies eligible for pooling.
doi:10.1371/journal.pone.0025164.g001
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2=moderate, 3=strong) with H-score above median [41,44] or $2
[23] designated ERCC1 high; a further four studies used the same
intensity score but a different extent score (0–1; 0=none, 0.1=1–9%,
0.5=10–49%, 1$50%) with H-score .1 [21,28,36] or .0 [43]
designated ERCC1 high; one study [29] graded intensity as above,
multiplied this by the percentage of cells stained and used the median
H-score (10, range 0–240); whilst the remaining study [22] calculated
an H-score of 0–3 (0=no staining, 1=faint in ,10% cells, 2=weak/
moderate in .10% cells, 3=strong in .10% cells) with $2d e s i g -
nated ERCC1 high. In the remaining five studies, percentage of cells
staining was examined alone, with samples .10% [26,40,42], .25%
[33], or above median percentage [32] designated ERCC1 high.
In the eight RTqPCR-based studies six [24,27,31,35,38,39]
used fixed tumour specimens whilst two [30,37] used frozen
material. In all but one study the deltaCt mRNA method was
used, comparing gene of interest to an internal reference (APPBP2
[31], b-actin [24,27,35,38,39], or ribosomal 18S [37]). In the
remaining study Rosell et al. [30] normalised to both ribosomal
18S and a commercially available calibrator sample. Again,
varying thresholds were used to dichotomize ERCC1. Unbiased
thresholds used included median [24,27,30,31,35,39] (threshold
(T-) value range 1.4–9.0), or approximate median [37] (T-value
50) mRNA expression, whilst in one study a maximal x
2 method
to determine the optimal cut-off value contingent on post hoc
outcomes was used [38].
The observed median proportion of NSCLCs with high
ERCC1 expression was 46% (range 17–65%), and 50% (range
41–56%) respectively in studies using IHC and RTqPCR. In
Table 1. Summary of studies reporting ERCC1 expression and outcomes in non-small cell and small-cell lung cancer patients.
Study
No of
patients
*
Clinical
trial Stage Chemotherapy
ERCC1
Method
% high ERCC1
expression
NSCLC
Lord et al. [39] 56 Yes IIIB-IV Cisplatin/gemcitabine RTqPCR 50
Rosell et al. [38] (A) 31 Yes IIIB-IV Cisplatin/gemcitabine/vinorelbine RTqPCR 52
Rosell et al. [38] (B) 29 Yes IIIB-IV Gemcitabine/vinorelbine and vinorelbine/ifosfamide RTqPCR 41
Simon et al. [37] 51 No Resected IA-IIIB None
e RTqPCR ,50
Olaussen et al. [36] (A) 389 Yes I-III Adjuvant cisplatin/etoposide or cisplatin/vinca alkaloid IHC 42
Olaussen et al. [36] (B) 372 Yes I-III None IHC 46
Ceppi et al. [35] 61 Yes IIIA-IV Cisplatin/gemcitabine or gemcitabine monotherapy RTqPCR 56
Booton et al. [31] 66 Yes IIIA-IV Carboplatin/docetaxel or MIC or MVP RTqPCR 50
Zeng et al. [34] 184 No Resected IA-IB None IHC 50
Rosell et al. [30] 126 No Resected I-IIIA None RTqPCR 50
Azuma et al. [33] 67 No Recurrent Platinum doublet IHC 43
Lee et al. [29] 130 No Resected I-III None IHC 62
Fujii et al. [32] (A) 15 Yes IIIA-IIIB Neo-adjuvant cisplatin/irinotecan IHC 47
Fujii et al. [32] (B) 20 Yes IIIA-IIIB Neo-adjuvant chemoRT; cisplatin/docetaxel IHC 65
Okuda et al. [28] (A) 90 No Resected I-IV Neo-adjuvant or adjuvant platinum doublet IHC 43
Okuda et al. [28] (B) 59 No NS None IHC 34
Hwang et al. [21] 68 No IIIA Neo-adjuvant chemoRT; platinum doublet IHC 46
Lee et al. [41] 50 No IIIB/IV/recurrent Platinum doublet IHC 56
Azuma et al. [22] 34 No IIB-IIIB Concurrent chemoRT; cisplatin/docetaxel IHC 47
Ota et al. [26] 156 No IV Platinum doublet IHC 64
Wang et al. [42] 124 No IIIB-IV Cisplatin doublet IHC 35
Holm et al. [43] 163 No Inoperable IIB-IV Carboplatin/gemcitabine IHC 43
Jeong et al. [44] 39 No III ChemoRT; cisplatin doublet or triplet IHC 31
Bartolucci et al. [24] 54 No Resected IB-IIB None RTqPCR 50
SCLC
Ceppi et al. [27] (A) 40 No Extensive Cisplatin/carboplatin and etoposide RTqPCR 51¯
|
Ceppi et al. [27] (B) 45 No Limited Cisplatin/carboplatin and etoposide RTqPCR
Lee et al. [23] (A) 37 No Extensive Platinum doublet IHC 17¯
|
Lee et al. [23] (B) 40 No Limited Platinum doublet IHC
Kim et al. [40] 130 No Extensive (86%) Platinum-based combination IHC 28
RTqPCR, reverse transcriptase quantitative polymerase chain reaction; IHC, immunohistochemistry; MIC, mitomycin/ifosfamide/cisplatin; MVP, mitomycin/vinblastine/
cisplatin; chemoRT, chemoradiotherapy; NS, not stated;
*, number of patients assessable for ERCC1 expression and overall survival;
e, one patient received adjuvant chemoradiotherapy;
¯
|, % high ERCC1 expression overall (data not stated for subgroups separately).
doi:10.1371/journal.pone.0025164.t001
ERCC1 and Lung Cancer Outcome
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25164SCLC, the two studies using IHC reported 17% [23] and 28%
[40] high expression, and 51% in the study using RTqPCR [27].
Survival data extracted from studies
Of the 23 studies providing data for meta-analysis, there were
16 studies in regard OS in patients with NSCLC who received
platinum-containing chemotherapy; one study in regard NSCLC
patients receiving a non-platinum-containing regimen; seven
studies in regard NSCLC patients undergoing surgery alone,
and five studies for SCLC patients (Table 2). Although most
studies (n=23) provided unadjusted results [21,22,23,24,26,27,
28,29,30,31,32,33,34,35,37,38,39,40,41,44], fewer studies (n=17)
provided adjusted results [21,22,23,24,26,27,28,29,31,33,36,37,
39,41,42,43]. Eleven datasets were available for pooling EFS, all
with unadjusted [21,22,24,26,30,32,33,34,38], and five with
adjusted [21,22,24,26,33] datapoints (Table 2). Mean follow-up
time data were presented by most investigators, with a median of
15 months for non-resected NSCLC (range 11–24), and 48
months for resected NSCLC (range 30–106). In the three studies
investigating SCLC, mean follow-up was unreported [27], 12
months [23], and 100 months [40]
Direct evidence for predictive influence of ERCC1
Only one study [36], based on a subset of 761 of 1,867 trial
patients, provided direct evidence on ERCC1 as a predictive
biomarker in the form of an interaction between randomised
Table 2. Results of survival analyses by individual study.
Overall Survival Event Free Survival
Study Univariate Multivariate Univariate Multivariate
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
NSCLC No Chemotherapy
Simon et al. [37] 0.34 0.14–0.83 0.24 0.08–0.77 — — — —
Olaussen et al. [36] (B) — — 0.66 0.49–0.90 — — — —
Zeng et al. [34] 0.54
* 0.34–0.86
* — — 0.64
* 0.38–1.10
* ——
Rosell et al. [30] 0.96
* 0.53–1.74
* — — 0.96
* 0.51–1.79
* ——
Lee et al. [29] 0.61
* 0.38–0.99
* 0.60 0.36–1.00 — — — —
Okuda et al. [28] (B) 1.68
* 0.69–4.06
* 1.62 0.71–3.70 — — — —
Bartolucci et al. [24] 2.07
* 0.94–4.54
* 1.17 0.62–2.21 1.71
* 0.78–3.76
* 1.15 0.56–2.37
NSCLC Platinum Treated
Lord et al. [39] 2.39
* 1.24–4.59
* 3.13 1.41–7.14 — — — —
Rosell et al. [38] (A) 0.59
* 0.26–1.30
* — — 0.92
* 0.45–1.91
* ——
Olaussen et al. [36] (A) — — 1.16 0.86–1.56 — — — —
Ceppi et al. [35] 2.28
* 1.32–3.94
* —— — — ——
Booton et al. [31] 0.91
* 0.45–1.85
* 0.96 0.92–1.00 — — — —
Azuma et al. [33] 2.99
* 1.60–5.59
* 1.65 1.21–2.28 2.22
* 1.24–3.97
* 1.37 1.07–1.76
Fujii et al. [32] (A) 1.48
* 0.45–4.82
* — — 1.65
* 0.48–5.71
* ——
Fujii et al. [32] (B) 1.85
* 0.30–11.65
* — — 0.62
* 0.15–2.65
* ——
Okuda et al. [28] (A) 2.43
* 1.28–4.61
* 2.31 1.24–4.31 — — — —
Hwang et al. [21] 2.14
* 1.17–3.93
* 2.07 1.03–4.17 1.77
* 0.97–3.23
* 1.57 0.83–2.98
Lee et al. [41] 1.79
* 0.99–3.25
* 3.16 1.54–6.46 — — — —
Azuma et al. [22] 1.73
* 0.74–4.09
* 2.41 0.86–6.76 2.79
* 1.29–6.03
* 3.97 1.41–11.23
Ota et al. [26] 1.46
* 1.04–2.05
* 1.33 0.93–1.92 0.69
* 0.47–1.02
* 1.22 0.79–1.85
Wang et al. [42] — — 1.72 1.16–2.53 — — — —
Holm et al. [43] — — 1.24 1.01–1.51 — — — —
Jeong et al. [44] 0.64
* 0.32–1.28
* —— — — ——
NSCLC Non-Platinum Treated
Rosell et al. [38] (B) 0.77
* 0.34–1.74
* — — 1.08
* 0.52–2.26
* ——
SCLC
Ceppi et al. [27] (All patients) 1.46
* 0.94–2.26
* —— — — ——
Ceppi et al. [27] (B; LS) 2.19
* 1.19–4.04
* 2.06 1.18–4.38 — — — —
Lee et al. [23] (A; ES) 0.82
* 0.37–1.79
* 1.07 0.46–2.49 — — — —
Lee et al. [23] (B; LS) 3.66
* 1.26–10.60
* 2.80 1.02–2.39 — — — —
Kim et al. [40] 0.90
* 0.61–1.35
* —— — — ——
HRs and associated 95% CIs are given as quoted unless stated otherwise, (—) indicates not assessed;
*estimated result from data presented in paper using methods of Palmer et al. (REF);
HR, hazard ratio; CI, confidence interval; LS, limited stage; ES, extensive stage.
doi:10.1371/journal.pone.0025164.t002
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(p=0.009), with adjuvant cisplatin-based chemotherapy prolong-
ing survival compared with observation in patients with ERCC1-
negative tumours (adjusted HR=0.65; 95%CI: 0.50–0.86) but not
in patients with ERCC1-positive tumours (adjusted HR=1.14;
95%CI: 0.84–1.55).
Indirect evidence for predictive influence of ERCC1
i) Relationship between ERCC1 status and survival in
NSCLC without systemic therapy. Seven datasets [24,28,29,
30,34,36,37] assessing 896 patients, with high ERCC1 expression
observed in 48% of tumours, were available for pooling estimates
of survival in patients who underwent surgery alone without
systemic therapy. Neither the meta-analysis of unadjusted nor
meta-analysis of adjusted estimates provided evidence that
ERCC1 status has prognostic value for either OS or EFS in
these patients (Table 3 and Figure 2).
ii) Relationship between ERCC1 status and survival in
NSCLC with platinum-based systemic therapy. OS HR
estimates obtained from 1,391 NSCLC patients who received
platinum were available for meta-analysis, 640 (46%) of whom had
tumours with high ERCC1 expression. Meta-analysis of the
unadjusted estimates indicated a significantly poorer OS in
patients with high ERCC1 expression (average HR=1.61,
Table 3. Meta-analysis results.
Meta-analysis of unadjusted estimates Meta-analysis of adjusted estimates
Studies n studies
Pooled
HR
Pooled
95% CIs
I
2
(%)
95%
prediction
interval
n
studies
Pooled
HR
Pooled
95% CIs
I
2
(%)
95%
prediction
interval
NSCLC platinum treated, OS 13 1.61 1.23–2.10 52 0.71–3.62 11 1.57 1.24–1.99 83 0.73–3.37
NSCLC platinum treated, EFS 7 1.36 0.83–2.21 82 0.30–6.05 4 1.46 1.09–1.95 32 0.56–3.81
NSCLC no chemotherapy, OS 6 0.82 0.51–1.31 68 0.19–3.59 5 0.75 0.49–1.16 61 0.19–2.92
NSCLC no chemotherapy, EFS 3 0.96 0.56–1.63 51 0.01–226 — — — — —
SCLC all patients, OS 3 1.33 0.85–2.09 62 0.01–190 — — — — —
SCLC limited stage, OS 2 2.49 1.86–4.23 0 — 2 2.26 1.30–3.91 0 —
OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0025164.t003
Figure 2. Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients not treated with
chemotherapy.
doi:10.1371/journal.pone.0025164.g002
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adjusted estimates (average HR=1.57, 95%CI: 1.24–1.99), and
was observed in patients treated in both the adjuvant and
advanced disease settings (Figure 3). However, large heterogeneity
was observed in both unadjusted and adjusted analyses (I
2=52%
and I
2=83%, respectively), resulting in wide prediction intervals
for the prognostic effect in an individual clinical setting, and whilst
there was no evidence of small study effects using unadjusted
estimates (Egger’s test: p=0.72), there was clear evidence of such
using adjusted estimates (Egger’s test: p,0.0001). Meta-analysis
for EFS indicated a relationship with ERCC1 status using adjusted
estimates (average HR=1.46, 95%CI:1.09–1.95, I
2=32%), but
not with unadjusted (Table 3), and investigation of small study
effects was not possible due to the small number of studies.
iii) Relationship between ERCC1 status and survival in
SCLC. Five studies were available in regard SCLC patients
receiving platinum-based chemotherapy (Table 2), contributing
data on 292 patients, of whom 92 (32%) had high ERCC1
expressing tumours. Meta-analysis of neither unadjusted nor
adjusted estimates indicated an association between OS and
high ERCC1 expression (Table 3). In an exploratory analysis
stratifying by stage of disease, there was evidence of association
between high ERCC1 expression and poor OS in limited stage
patients, although this was based on only 2 studies.
iv) Relationship between ERCC1 status and tumour
response. Tumour response stratified by ERCC1 expression
was reported by ten [21,22,26,31,32,33,39,41,42] NSCLC data-
sets comprising 656 patients, 328 (50%) of whom had high
expression. All patients were treated with platinum containing
chemotherapy. There was evidence that high ERCC1 was
associated with a reduced response to platinum (average
RR=0.80; 95%CI:0.64–0.99, Figure 4) with moderate
heterogeneity (I
2=25.3%) and no evidence of small study effects
(Egger’s test: p=0.36). Meta-analysis of three studies in SCLC
(292 patients), also provided evidence of a trend towards increased
response to platinum-containing chemotherapy in high ERCC1
expressing tumours (average RR=1.14; 95% CI: 0.99–1.31,
p=0.08; I
2=0%), although this was not statistically significant.
Discussion
Somatic molecular phenotype has become well established as a
key determinant in NSCLC in terms of both outcome and efficacy
of systemic therapy [46,47,48]. Previous studies have suggested
that somatic ERCC1 expression level is both prognostic in lung
cancer, and predictive of outcome to platinum-based chemother-
apy. Indeed, trials have already reported randomising patients
contingent on somatic ERCC1 status [49,50], with others actively
accruing. However, our analysis has shown that many of the
Figure 3. Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients receiving platinum-
based chemotherapy.
doi:10.1371/journal.pone.0025164.g003
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size, reported conflicting outcomes, and used widely differing
expression methodology and, in particular, threshold levels.
Only one study [36] directly assessed the predictive utility of
ERCC1 status for platinum-based chemotherapy in NSCLC, and
this was retrospective in design and in a subgroup of patients
recruited to a clinical trial. A relationship between ERCC1 and
survival in platinum-treated patients but not in non-platinum
treated patients provides indirect evidence that ERCC1 is
predictive, although the robustness of this conclusion is compro-
mised due to the non-randomised nature of the treatment groups.
Based on data from NSCLC patients untreated with systemic
therapy, our analyses do not support the hypothesis that ERCC1
expression is prognostic in NSCLC. However, tentative evidence
that, on average, high ERCC1 expression identifies poorer
survival in NSCLC patients treated with platinum-based chemo-
therapy, provided indirect evidence of a predictive influence,
although this may be merely a prognostic effect in this patient
group. The lower likelihood of response to platinum-based
chemotherapy in high ERCC1 expressing tumours observed
further supports the notion that ERCC1 might be predictive of
lack of platinum benefit.
Our study has identified several methodological weaknesses that
must be addressed. Firstly, we observed notable variation in cut-
offs in ERCC1 expression, which account in part for heterogeneity
observed. Second, there has been considerable debate as to
whether the 8F1 antibody clone specifically binds ERCC1 alone
or other non-ERCC1 epitopes [51,52]. Third, it is unclear
whether ERCC1 expression analysis by IHC and RTqPCR
stratify patients into similar groups [34], and in the absence of a
proven correlation between these two methods we recommend the
use of IHC since it is more readily available and more easily
standardised across laboratories. For ERCC1 to be a useful
predictive biomarker in clinical practice, a single clearly defined
protocol needs to be developed and validated to allow comparison
of outcomes across studies. Inadequate sample size was also a
frequent problem in the studies included in our analyses, with only
eight of the 23 studies reporting outcomes from over 100 patients.
Whilst pooling data may in part address deficiencies in individual
study sample sizes, smaller studies are more likely to generate
heterogeneity, as we observed. Several independent studies, each
an order of magnitude greater than most published series, are
required to allow accurate estimation of the true associations
between ERCC1 expression and outcomes in lung cancer patients,
particularly in SCLC.
Strengths of our study include the analysis of both survival and
chemotherapy response endpoints, the separate meta-analysis of
studies in which patients did or did not receive chemotherapy
allowing an assessment of both predictive and indirect prognostic
influences, calculation of prediction intervals to estimate the range
of potential effects in any one individual study, and extensive
comparison of study methodologies. In contrast, a similar recently
published meta-analysis [53] made no assessment of the influence
of ERCC1 status in patients who did not receive chemotherapy or
SCLC patients, did not account for adjusting and made no
assessment of methodological differences between contributing
studies, failed to use the published HR and CIs for one study
which compromised assessment of publication bias, used fixed
Figure 4. Forest plot showing the meta-analysis of unadjusted relative risk estimates for response rate in NSCLC patients receiving
platinum-based chemotherapy.
doi:10.1371/journal.pone.0025164.g004
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ity, and included potentially overlapping datasets. In our study we
did not assess the quality of the primary studies, however quality
assessment tools for examining prognostic and predictive bio-
marker studies do not currently exist, and are only beginning to be
discussed for prognosis studies in general [54].
Large heterogeneity, methodological concerns, and potential for
publication bias revealed by our analyses indicate that although
ERCC1 shows considerable promise as a predictive biomarker in
platinum-treated NSCLC patients, it is not ready for ‘prime-time’.
International consensus is urgently required to mandate homoge-
neous ERCC1 assessment methodology, as are prospective trials
sufficiently powered to detect an interaction between platinum
chemotherapy and ERCC1 expression, and in the interim,
initiation of large, prospectively planned individual patient data
meta-analyses. Until then, ERCC1 expression should not be
routinely used in clinical decision-making.
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